"BMS068645 is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials."@en . . . "# Cerqueira MD: Advances in pharmacologic agents in imaging: new A2A receptor agonists. Curr Cardiol Rep. 2006 Mar;8(2):119-22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16524538"@en . . "250386-15-3"@en . "BMS068645 is designed to selectively stimulate the A2a adenosine receptor responsible for coronary vasodilation. Research to date suggests that this compound could potentially reduce or eliminate side effects associated with currently available pharmacologic stress agents that are not selective for the A2a adenosine receptor."@en . . . . . . . . . . . . . . . . . . . "investigational"@en . . . "BMS068645"@en . . . . . "Investigated for use/treatment in cardiovascular disorders and inflammatory disorders (unspecified)."@en . . . . . .